Cedric Francois, Chief Executive Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 499,587 shares at $64.92 ($32.0M) on 2024-03-01, disclosed to the SEC on 2024-03-05.
Scheduled sale ($32.0M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $62.21 | 28,868 | $1.8M | 5.6% |
| 2 | $62.21 | 28,868 | $1.8M | 5.6% |
| 3 | $62.96 | 41,704 | $2.6M | 8.2% |
| 4 | $62.96 | 41,704 | $2.6M | 8.2% |
| 5 | $64.26 | 62,503 | $4.0M | 12.5% |
| 6 | $64.26 | 62,503 |
| $4.0M |
| 12.5% |
| 7 | $64.92 | 116,512 | $7.6M | 23.6% |
| 8 | $64.92 | 116,512 | $7.6M | 23.6% |
| 9 | $65.68 | 413 | $27K | 0.1% |
| Total | $64.12 avg | 499,587 | $32.0M | 100% |
| Filing → |
| APLS | SELL | 2026-01-15 | $226K | — | Filing → |
| APLS | SELL | 2025-08-29 | $12.7M | — | Filing → |
| APLS | SELL | 2025-07-18 | $797K | — | Filing → |